The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients with Symptomatic Peripheral Vascular Disease from Stenosis or Occlusion of the Femoropopliteal Artery

Inclusion Criteria: * Symptomatic peripheral vascular occlusive disease (Rutherford-Becker Clinical Category 2-4) * Patient with life expectancy \>36 months * Females of childbearing potential must have negative pregnancy test * Patient is able to provide informed consent * Patient agrees to undergo all protocol-required follow-up examinations and requirements at the investigational site. * Patient must be able to take antiplatelet and/or anticoagulant agents as prescribed * Single de novo native disease segment of the superficial femoral artery (SFA) or P1 popliteal segment * Reference vessel diameter ≥5.5 mm and ≤6.5 mm * Target lesion length ≤90 mm * Target lesion with ≥50% DS * Inflow artery and popliteal artery free from flow-limiting lesion (DS \<50%) Exclusion Criteria: * Hemoglobin \<9.0 g/dL * WBC \<3,000 cells/mm3 * Platelet count \<80,000 cells/mm3 or \>700,000 cells/mm3 * Acute or chronic renal dysfunction with creatinine \>2.5 mg/dl (176 µmol/L) * Severe liver impairment as defined by total bilirubin ≥3 mg/dl or two times increase over the normal level of SGOT or SGPT * A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticagrelor or sirolimus, or with contrast sensitivity for which the patient cannot be adequately pre-medicated * Patient requires a planned procedure that would necessitate discontinuation of antiplatelet therapy * Patient is unable to walk * Patient has undergone a percutaneous vascular intervention \<30 days prior to the planned index procedure * Patient is maintained on chronic hemodialysis * Patient has uncontrolled diabetes mellitus (HbA1c ≥7.0%). * Patient has had a myocardial infarction within the previous 30 days of the planned index procedure * Patient has had a stroke within the previous 30 days of the planned index procedure and/or has deficits from a prior stroke that limits the patient's ability to walk * Patient has unstable angina defined as rest angina with ECG changes * Patient has a local groin or acute systemic infection that has not been treated successfully or is currently under treatment * Patient has acute thrombophlebitis, deep vein thrombosis or chronic venous insufficiency in either extremity * Patient has other medical illnesses (e.g., cancer, congestive cardiomyopathy, etc.) that may cause the patient to be non-compliant with protocol requirements, confound the data interpretation or will prevent completion of all required follow up assessments through 36 months * Patient is currently participating in an investigational drug, biologic, or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints * Patient has ischemic or neuropathic ulcers on either foot * Patient has undergone minor or major amputation of either lower extremity * Patient is part of a vulnerable population who, in the judgment of the Investigator, is unable to give informed consent * Target extremity with an angiographically significant (\>50% DS) lesion located distal to the target lesion that requires treatment at the time of the index procedure or by a staged procedure * Acute arterial ischemia of the target extremity * Target extremity has been previously treated with open surgical revascularization (bypass or endarterectomy) * Target vessel has been previously treated with stent, laser, atherectomy, surgical bypass, or endarterectomy * Total occlusion (100% DS) of the ipsilateral inflow artery * Angiographic evidence of thrombus in the target vessel * The target lesion requires treatment with a device other than percutaneous transluminal balloon angioplasty (PTA) \[e.g., orbital atherectomy, directional atherectomy, excimer laser, rotational atherectomy, cryoplasty, etc.\] * Target lesion is within or adjacent to an aneurysm * Patient has angiographic evidence of thromboembolism or atheroembolism from treatment of an ipsilateral iliac lesion or from crossing or pre-dilating the target lesion * Target lesion has moderate-to-severe calcification * Target lesion with \> 30% residual stenosis following pre-dilatation